C
CellCentric
United Kingdom · Biotech · Healthtech
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series D | $220M | American Cancer Society BrightEdge — Role not disclosedAvego BioScience Capital — Role not disclosedFidelity Management & Research Company — Role not disclosedForbion — Role not disclosedHBM Healthcare — Role not disclosedPfizer — Role not disclosedRA Capital Management — Role not disclosedSofinnova Partners — Role not disclosedVenrock Healthcare Capital Partners — Role not disclosed |